Clinical features, disease stage, final nodal size (relative to baseline CT), and patient outcome
| Patient No. | Lesion No. | Age, yr | Sex | Stage | BRAF Status | Location | Final Lesion Size | Patient Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 63 | F | T3bN3M1a | Negative | Left supraclavicular | Decreased | Remission. |
| 2 | 2 | 66 | M | TxNxM1c | Wild type | Right supraclavicular | Decreased | T-VEC discontinued after disease progression in ribs. Placed on nivolumab with partial response. |
| 3 | Right supraclavicular | Decreased | ||||||
| 3 | 4 | 40 | M | pT1bN3M1c | Positive | Right preauricular | Decreased | IL-2 followed by BRAF and MEK inhibitors after ipilimumab/T-VEC treatment. Deceased. |
| 5 | Right submandibular | Decreased | ||||||
| 4 | 6 | 44 | M | T3bN3M1b | Positive | Right axillary | Decreased | BRAF and MEK inhibitors after ipilimumab/T-VEC treatment, followed by disease progression. Deceased. |
| 7 | Right axillary | Decreased | ||||||
| 5 | 8 | 58 | F | T3bN2M1a | Wild type | Left upper back | Decreased | Complete response for 21 months, followed by axillary recurrence. Placed on nivolumab. |
| 9 | Left breast | Decreased | ||||||
| 6 | 10 | 32 | M | T4bN3M1a | Negative | Left retroauricular | Decreased | Partial response for 6 months. Placed on nivolumab. |
| 7 | 11 | 63 | M | T3aN3M1c | Negative | Right chest wall | Increased | Rapid deterioration after brain metastases. Deceased. |
| 12 | Right axilla | Decreased |
Note:—IL-2 indicates interleukin 2.